GR1802 injection
Sponsors
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions
Allergic RhinitisAllergic Rhinitis, SeasonalAsthmaAtopic DermatitisChronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis with Nasal Polyps
Phase 2
The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps
Active, not recruitingNCT05873803
Start: 2023-02-08End: 2024-12-30Target: 70Updated: 2024-09-25
The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT06015243
Start: 2023-08-18End: 2025-03-30Target: 70Updated: 2023-08-29
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
Active, not recruitingNCT06315426
Start: 2024-03-24End: 2025-10-31Updated: 2025-04-25
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma
NCT06642961
Start: 2022-07-19End: 2025-12-31Target: 150Updated: 2024-10-15
Phase 3
Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis
Not yet recruitingNCT06216392
Start: 2024-01-31End: 2026-01-31Target: 450Updated: 2024-01-22
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis
RecruitingNCT07154342
Start: 2025-08-15End: 2026-07-31Target: 150Updated: 2025-09-04
A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.
Not yet recruitingNCT07199257
Start: 2025-09-25End: 2027-07-31Target: 144Updated: 2025-09-30